2005-07-18

The Phase I study, which comprised a total of 30 healthy volunteers, was performed in cooperation with the Phase I unit at the Karolinska University Hospital in Stockholm.

The results show that 57-57 is very well tolerated in all of the studied dose levels, both as single and repeated dose, and that it is well suitable to be given as an oral, daily treatment.

Preparations for a patient study (Phase I) with 57-57 are ongoing. This study is planned to start before year end.

Lund, July 18, 2005

Active Biotech AB (publ)

Sven Andréasson

President & CEO

For further information, please contact:

Sven Andréasson, President& CEO, +46 46-19 20 49

Hans Kolam, CFO, +46 46-19 20 44

Cecilia Hofvander, Manager Corporate Communication, +46 46-19 11 22

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA.